A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG)
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Hanauske, A. R. | en |
dc.contributor.author | Gamucci, T. | en |
dc.contributor.author | Smyth, J. F. | en |
dc.contributor.author | Lehnert, M. | en |
dc.contributor.author | Velde, A. Te | en |
dc.contributor.author | Lan, J. | en |
dc.contributor.author | Verweij, J. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Hanauske, A. R. | en |
dc.creator | Gamucci, T. | en |
dc.creator | Smyth, J. F. | en |
dc.creator | Lehnert, M. | en |
dc.creator | Velde, A. Te | en |
dc.creator | Lan, J. | en |
dc.creator | Verweij, J. | en |
dc.date.accessioned | 2018-06-22T09:54:19Z | |
dc.date.available | 2018-06-22T09:54:19Z | |
dc.date.issued | 1996 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42297 | |
dc.description.abstract | In a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bioreductive alkylating indoloquinone. The drug was given at two different dose schedules by a single bolus i.v. injection: arm A 12 mg/m2 weekly and arm B 22 mg/m2 every three weeks. All together 185 courses were administered (145 in arm A and 40 in arm B). The major toxicity was reversible proteinuria more frequently occurring in the three-weekly schedule (arm A 34.5% vs. arm B 62.5%). Creatinine elevation, fluid retention and pericardial or pleural effusion were also recorded in a limited number of patients. Other common toxicities more frequent in the three-weekly administration were asthenia (21% vs. 35% of cycles), nausea (15% vs. 27.5% of cycles) and Vomiting (5% vs. 17.5% of cycles). Toxicities were mainly of grade I and II. No responses have been observed. Five patients (26%) on arm A and eight (53%) on arm B experienced stable disease. These doses and schedules of EO9 do not yield activity in NSCLC. | en |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Human | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Priority journal | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Multicenter study | en |
dc.subject | Randomized controlled trial | en |
dc.subject | Lung non small cell cancer | en |
dc.subject | Male | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Vomiting | en |
dc.subject | Nausea | en |
dc.subject | 5 (1 aziridinyl) 3 hydroxymethyl 2 (3 hydroxy 1 propenyl) 1 methyl 4 | en |
dc.subject | 7 indoledione | en |
dc.subject | Eo9 | en |
dc.subject | Nsclc | en |
dc.subject | Toxicity | en |
dc.subject | Indoloquinoline derivative | en |
dc.subject | Indoloquinone | en |
dc.subject | Nephrotoxicity | en |
dc.title | A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG) | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/oxfordjournals.annonc.a010645 | |
dc.description.volume | 7 | |
dc.description.issue | 5 | |
dc.description.startingpage | 529 | |
dc.description.endingpage | 531 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |